Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate

Clinical Chemistry

Volumn 52, Issue 3, 2006, Pages 453-457

  Charlton Menys, Valentine ^a   Liu, Yifen ^a   Durrington, Paul N ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ORGANOPHOSPHATE;

ANALYTIC METHOD; ARTICLE; ATHEROSCLEROSIS; AUTOMATION; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; COST; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SUBSTRATE; NON INSULIN DEPENDENT DIABETES MELLITUS; RELIABILITY; SAFETY; SPECTROPHOTOMETRY;

ARYLDIALKYLPHOSPHATASE; CALCIUM; ENZYME TESTS; HUMANS; HYDROLYSIS; PARAOXON;

EID: 33644523071     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.063412     Document Type: Article

References (20)

1. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-80.
2. Berliner JA, Heinecke JW. The role of oxidised lipoprotein in atherogenesis. Free Radic Biol Med 1996;20:707-27.
3. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler Suppl 2002;3:49-55.
4. Mackness B, Durrington P, Povey A, Thomson S, Dippnall M, Mackness M, et al. paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. Pharmacogenetics 2003;13:81-8.
5. Lee BW, London L, Paulauskis J, Myers J, Christiani DC. Association between human paraoxonase gene polymorphism and chronic symptoms in pesticide-exposed workers. J Occup Environ Med 2003;45:118-22.
6. Sözmen EY, Mackness B, Sözmen B, Durrington P, Girgin FK, Aslan L, et al. Effect of organophosphorus intoxication on human serum paraoxonase. Hum Exp Toxicol 2002;21:47-52.
7. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly prospective study. Circulation 2003;107:2775-9.
8. Tomás M, Sentí M, García-Faria F, Torrents A, Covas M, Marrugat J. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000;20:2113-9.
9. Furlong CE, Richter RJ, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988;43:230-8.
10. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995;15:1812-8.
11. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abaisha B, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998;139:341-9.
12. James RW, Leviev I, Ruiz J, Passa P, Froguel P, Garin M-C B. Promoter polymorphism T(-107)C of the paraoxonase gene PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 2000;49:1390-3.
13. Evelson P, Gambino G, Travacio M, Jaita G, Verona J, Maroncelli C, et al. Higher antioxidant defenses in plasma and low density lipoproteins from rugby players. Eur J Clin Invest 2002;32:818-25.
14. Lee M-K, Park E-M, Bok S-H, Jung UJ, Kim J-Y, Park YB, et al. Two cinnamate derivatives produce similar alteration in mRNA expression and activity of antioxidant enzymes in rats. J Biochem Mol Toxicol 2003;17:255-62.
15. Hasselwander O, Savage DA, McMaster D, Loughrey CM, McNamee PT, Middleton D, et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 1999;56:289-98.
16. Horter MJ, Sonderman S, Reinecke H, Bogdanski J, Woltering A, Kerber S, et al. Associations of HDL phospholipids and paraoxonase activity with coronary heart disease in postmenopausal women. Acta Physiol Scand 2002;176:123-30.
17. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999;9:745-53.
18. Rainwater DL, Mahaney MC, Wang XL, Rogers J, Cox LA, Vandeberg JL. Determinants of variation in serum paraoxonase enzyme activity in baboons. J Lipid Res 2005;46:1450-6.
19. Kuo CL, LaDu BN. Calcium binding by human and rabbit serum paraoxonases: structural stability and enzymatic activity. Drug Metab Dispos 1998;26:653-60.
20. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004;11:412-9.